WAVE Life Sciences (WVE) Receiving Somewhat Positive News Coverage, AlphaOne Reports

Headlines about WAVE Life Sciences (NASDAQ:WVE) have trended somewhat positive recently, Alpha One reports. Alpha One, a unit of Accern, scores the sentiment of news coverage by analyzing more than 20 million blog and news sources. Alpha One ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. WAVE Life Sciences earned a daily sentiment score of 0.23 on Alpha One’s scale. Alpha One also assigned news coverage about the company an impact score of 0 out of 100, indicating that recent news coverage is extremely unlikely to have an effect on the stock’s share price in the near term.

These are some of the news articles that may have effected AlphaOne’s scoring:

Insider Buying and Selling by Quarter for WAVE Life Sciences (NASDAQ:WVE)

Several analysts recently commented on WVE shares. HC Wainwright reissued a “buy” rating on shares of WAVE Life Sciences in a research report on Monday, March 27th. Jefferies Group LLC reissued a “buy” rating and set a $42.00 price objective on shares of WAVE Life Sciences in a research report on Wednesday, April 26th. Finally, JMP Securities reissued an “outperform” rating and set a $40.00 price objective on shares of WAVE Life Sciences in a research report on Friday, June 9th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $42.00.

Shares of WAVE Life Sciences (NASDAQ:WVE) opened at 20.25 on Thursday. The company’s 50-day moving average is $20.88 and its 200 day moving average is $26.33. The stock’s market capitalization is $561.27 million. WAVE Life Sciences has a 12 month low of $16.90 and a 12 month high of $40.15.

WAVE Life Sciences (NASDAQ:WVE) last announced its earnings results on Wednesday, May 10th. The company reported ($0.89) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.77) by $0.12. WAVE Life Sciences had a negative return on equity of 48.16% and a negative net margin of 3,172.14%. The firm had revenue of $0.68 million during the quarter, compared to the consensus estimate of $0.80 million. Equities research analysts predict that WAVE Life Sciences will post ($3.25) earnings per share for the current year.

In other news, Director Masaharu Tanaka sold 433,825 shares of the business’s stock in a transaction dated Wednesday, March 29th. The stock was sold at an average price of $24.91, for a total transaction of $10,806,580.75. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 62.25% of the stock is currently owned by insiders.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by sleekmoney and is owned by of sleekmoney. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://sleekmoney.com/wave-life-sciences-wve-receiving-somewhat-positive-news-coverage-alphaone-reports/1910933.html.

About WAVE Life Sciences

WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/wave-life-sciences-wve-receiving-somewhat-positive-news-coverage-alphaone-reports/1910933.html

Receive News & Ratings for WAVE Life Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *